습성 나이관련황반변성 치료제의 건강보험 적용 확대 및 다양화에 따른 치료 경향 분석

Abstract

Purpose: We analyzed the incidence and prevalence of neovascular age-related macular degeneration (AMD) treatment patterns AMD in response to changes health insurance policies South Korea.Methods: retrospectively patients diagnosed between 2010 2019. Data were extracted from Korean National Health Insurance System database. The per 10,000 person-years corresponding 95% confidence intervals calculated. Furthermore, we recorded usage ranibizumab aflibercept among newly with 2014.Results: In total, 90,012 increased age, except for individuals aged ≥ 90 years. significantly 30.29 50.8 rate intravitreal injections decreased following introduction 2014. Patients who switched exhibited a higher drug switch than those (28.83% vs. 8.40%). Among patients, approximately 65% received covered by system. On average, six administered year 2019; number accordance maximum limit supported government.Conclusions: demonstrated an increasing trend. are influenced government funding support policies. These findings provide valuable information planning treatment.